Apogee Therapeutics, Inc. Operating Cash Flow
Apogee Therapeutics, Inc. (APGE) reported Operating Cash Flow of -$126.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Apogee Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$71.38M.
- Apogee Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$55.57M.
- Apogee Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$62.69M.
- Apogee Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$54.26M.
- Apogee Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$227.45M.
- Apogee Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$171.17M.
- Apogee Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$74.76M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 8 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 11 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$71.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$126.95M 10-Q · filed 2026-08-10 | -$189.64M derived: sum of 3 quarters · filed 2026-08-10 | -$243.89M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$55.57M 10-Q · filed 2026-05-11 | -$118.26M derived: sum of 2 quarters · filed 2026-05-11 | -$172.51M derived: sum of 3 quarters · filed 2026-05-11 | -$234.54M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$62.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$116.94M derived: sum of 2 quarters · filed 2026-03-02 | -$178.97M derived: sum of 3 quarters · filed 2026-08-10 | -$227.45M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | -$54.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$116.28M derived: sum of 2 quarters · filed 2026-08-10 | -$164.76M 10-Q · filed 2025-11-10 | -$232.47M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | -$62.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$110.51M 10-Q · filed 2026-08-10 | -$178.22M derived: sum of 3 quarters · filed 2026-08-10 | -$220.74M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$48.48M 10-Q · filed 2026-05-11 | -$116.19M derived: sum of 2 quarters · filed 2026-05-11 | -$158.72M derived: sum of 3 quarters · filed 2026-05-11 | -$188.01M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | -$67.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$110.24M derived: sum of 2 quarters · filed 2026-03-02 | -$139.54M derived: sum of 3 quarters · filed 2026-03-02 | -$171.17M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | -$42.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$71.82M derived: sum of 2 quarters · filed 2025-11-10 | -$103.46M 10-Q · filed 2025-11-10 | -$133.21M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-06-30 | -$29.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$60.94M 10-Q · filed 2025-08-11 | -$90.69M derived: sum of 3 quarters · filed 2026-03-02 | -$110.57M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-03-31 | -$31.64M 10-Q · filed 2025-05-12 | -$61.39M derived: sum of 2 quarters · filed 2026-03-02 | -$81.27M derived: sum of 3 quarters · filed 2026-03-02 | -$95.84M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2023-12-31 | -$29.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$49.63M derived: sum of 2 quarters · filed 2026-03-02 | -$64.20M derived: sum of 3 quarters · filed 2026-03-02 | -$74.76M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | -$19.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$34.45M derived: sum of 2 quarters · filed 2024-11-12 | -$45.01M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$14.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$25.13M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | -$10.56M 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | -$16.43M 10-K · filed 2024-03-05 | |||||
| 2022-09-30 | -$7.24M 10-Q · filed 2023-11-13 |